China's medical products administrator granted Broncus Holding (HKG:2216) marketing approval for its disposable lung radiofrequency ablation catheter, according to a Monday filing with the Hong Kong bourse.
The device, branded BroncAblate, will help with ultra-minimally invasive interventional therapy for lung cancer, the filing said.
Lung radiofrequency ablation uses heat generated by radio waves to destroy cancer cells.
Shares in Broncus soared 35% during morning trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.